Pharmaceutical Manufacturing Process: GMP, QA/QC, Validation, Equipment & FDA Requirements

Pharmaceutical manufacturing process showing GMP, QA QC, validation, equipment, packaging and batch release

Published by: Pharma Quality System Editorial Team • Editorial basis: FDA 21 CFR Parts 210 and 211, FDA Process Validation guidance, ICH Q8(R2), Q9(R1), Q10 and Q13, and Health Canada GUI-0001 and GUI-0029

RAW MATERIALS • PRODUCTION • IN-PROCESS CONTROL • VALIDATION • QC • RELEASE • LIFECYCLE

Pharmaceutical manufacturing is a controlled lifecycle system-not simply a sequence of machines. Materials, facilities, equipment, procedures, people, process parameters, testing, documentation and quality oversight must work together to consistently produce medicines that meet their intended identity, strength, quality and purity.

Quick answer

The pharmaceutical manufacturing process typically moves from approved raw materials through dispensing, processing, in-process controls, packaging, laboratory testing, quality review and batch release. The exact unit operations depend on the dosage form. Under GMP, critical processes and equipment must be appropriately controlled and qualified, manufacturing procedures must be approved and followed, deviations must be documented and investigated, and process performance must remain in a state of control throughout the commercial lifecycle.

Important regulatory nuance:
There is no single universal manufacturing flow for every pharmaceutical product. A tablet, oral solution, topical cream, sterile injectable and biologic require different process designs and contamination controls. FDA CGMP establishes outcome-oriented requirements for controlled manufacturing; it does not require every manufacturer to use the same equipment, the same number of process steps, or one fixed validation template. The process and control strategy must be appropriate for the product, technology, risk and approved application.

Table of Contents

What Is Pharmaceutical Manufacturing?
Why GMP Controls the Manufacturing System
End-to-End Pharmaceutical Manufacturing Process
Raw Materials, Suppliers & Component Control
Dispensing and Weighing
Tablet & Capsule Manufacturing
Liquid & Semi-Solid Manufacturing
Sterile Manufacturing — High-Level Overview
CQAs, CPPs & In-Process Controls
Equipment, Facilities & Utilities
QA, QC and the Quality Unit
Process Validation Lifecycle
Cleaning & Contamination Control
Batch Records, Documentation & Data Integrity
Packaging and Labeling
Finished-Product Testing and Batch Release
Stability and Lifecycle Monitoring
Batch vs Continuous Manufacturing
Scale-Up and Technology Transfer
Deviations, OOS, OOT, Change Control & CAPA
FDA Manufacturing Expectations
Health Canada Manufacturing Expectations
2026 FDA Warning-Letter Lessons
Common Manufacturing Mistakes
Interview Questions
FAQ

What Is Pharmaceutical Manufacturing?

Pharmaceutical manufacturing is the controlled conversion of approved starting materials into a drug substance, intermediate, bulk product or finished dosage form that consistently meets predefined quality requirements. For a finished drug product, manufacturing can include material receipt and testing, dispensing, blending or solution preparation, granulation, drying, milling, compression, encapsulation, coating, filling, sterilization where applicable, packaging, testing, storage and release.

Manufacturing is therefore broader than the physical act of producing tablets or filling bottles. It includes the quality systems that make the operation reproducible and traceable: approved procedures, qualified personnel, controlled facilities, suitable equipment, validated processes, calibration, sanitation, laboratory controls, deviation management, change control, data governance and ongoing monitoring.

Manufacturing principle:
Quality cannot be reliably created by final-product testing alone. It must be designed into the product and process, controlled during manufacture, verified by appropriate testing, and maintained through the product lifecycle.

This article focuses mainly on finished pharmaceutical drug-product manufacturing. Active pharmaceutical ingredient (API) manufacturing has important additional expectations under ICH Q7 and ICH Q11 and is best treated as a dedicated topic.

Why GMP Controls the Pharmaceutical Manufacturing System

In the United States, finished pharmaceutical manufacturing is governed principally by 21 CFR Parts 210 and 211. These CGMP requirements cover areas such as organization and quality-unit responsibilities, buildings and facilities, equipment, components and containers, production and process controls, packaging and labeling, laboratory controls, records and reports.

FDA's Quality Systems guidance explains that a modern quality-system approach can be used while remaining fully compliant with CGMP. ICH Q10 complements this by describing a lifecycle pharmaceutical quality system that connects process performance, product quality monitoring, CAPA, change management and management review.

Health Canada GUI-0001 similarly describes GMP as part of quality assurance and emphasizes that manufacturing processes should be clearly defined, systematically reviewed, capable of consistently producing the required quality, and supported by validated critical steps, suitable equipment, approved procedures, qualified personnel, correct materials and appropriate storage and transport.

For a deeper GMP overview, see GMP in Pharmaceutical Industry.

End-to-End Pharmaceutical Manufacturing Process

Typical Drug-Product Manufacturing Lifecycle

1
Materials

→

2
Dispensing

→

3
Processing

→

4
IPC

→

5
Bulk

→

6
Packaging

→

7
QC Testing

→

8
QA Release

→

9
Lifecycle

A simplified commercial workflow often looks like this:

Receipt and quarantine: incoming components and packaging materials are identified, controlled and held pending appropriate disposition.
Sampling and testing: materials are sampled under controlled procedures and evaluated against approved specifications.
Release for use: only appropriately released materials are issued to production.
Dispensing: approved materials are weighed or measured against the master manufacturing instructions.
Manufacturing: unit operations are performed according to the dosage-form process and approved parameter ranges.
In-process control: critical attributes and process conditions are monitored to detect variation before the batch reaches the end of the process.
Bulk handling: intermediates or bulk product are held under defined conditions and within justified hold times.
Packaging and labeling: finished dosage units are placed into the approved container-closure system and correctly labeled.
Laboratory testing: required chemical, physical and microbiological tests are performed using approved methods.
Batch review and disposition: the quality unit reviews relevant manufacturing and laboratory records, deviations and investigations before release or rejection.
Post-release lifecycle: stability, complaints, trends, deviations, changes and continued process performance continue to generate knowledge about the product.

The sequence can differ. For example, sterile manufacturing adds specialized contamination-control and sterilization or aseptic-processing steps, while continuous manufacturing can integrate several traditional unit operations into a connected system.

Pharmaceutical manufacturing process workflow from raw materials and dispensing through manufacturing QC QA and batch release

Raw Materials, Suppliers and Component Control

A robust manufacturing process starts before production begins. Variability in APIs, excipients, processing aids, water, gases and packaging materials can directly affect process performance and finished-product quality.

Material controls typically include:

approved specifications and sampling plans;
supplier qualification and ongoing supplier oversight;
identity testing and appropriate verification of supplier data;
quarantine, released and rejected status controls;
appropriate storage conditions;
retest or expiry controls where applicable;
traceability of lot numbers into the manufactured batch;
evaluation of material variability during process development and lifecycle monitoring.

Do not treat a supplier Certificate of Analysis as an automatic substitute for material control.
U.S. CGMP includes specific requirements for component testing and for establishing the reliability of a supplier's analyses when those results are relied upon. Supplier qualification and incoming-material controls should therefore be scientifically and procedurally justified.

Dispensing and Weighing in Pharmaceutical Manufacturing

Dispensing is the controlled weighing or measuring of raw materials for a specific batch. It sounds simple, but an error here can propagate through the entire batch.

Good controls commonly address:

correct material identity and released status;
correct lot and quantity;
appropriate calibrated balance or measuring equipment;
independent verification when required by the procedure;
line clearance and prevention of material mix-ups;
dust containment and cross-contamination control;
labeling and traceability of dispensed containers;
yield and reconciliation calculations.

The manufacturing record should allow a reviewer to reconstruct what material was used, how much was used, who performed the operation, what equipment was used and whether the step met the approved instructions.

Tablet and Capsule Manufacturing - Typical Oral Solid-Dose Processes

Oral solid dosage forms are useful for illustrating how manufacturing routes differ even within one dosage-form family. Tablets may be produced by direct compression, wet granulation or dry granulation, depending on material and product characteristics.

1. Direct Compression

A simplified direct-compression process may include dispensing → screening/sieving → pre-blending → lubrication → compression → optional coating → packaging. It can be efficient because it avoids a granulation and drying step, but it requires a formulation with suitable flow, compressibility and blend-uniformity behavior.

2. Wet Granulation

A typical wet-granulation route may include dispensing → dry mixing → binder preparation/addition → wet granulation → wet screening → drying → milling/sizing → final blending/lubrication → compression → coating → packaging.

Potentially important parameters can include granulation endpoint, binder addition, impeller/chopper conditions, drying temperature and endpoint, mill screen and speed, final blend time, compression force, turret speed and coating conditions. The actual CPPs must be identified from product and process knowledge rather than copied from a generic list.

3. Dry Granulation

Dry granulation can be used when moisture or heat exposure is undesirable. A roller-compaction route may include dispensing → pre-blend → roller compaction → milling → lubrication/final blending → compression. Ribbon density, roll force, gap, milling conditions and downstream tablet attributes may require careful control.

Common Tablet In-Process Tests

Depending on the process and registered controls, in-process monitoring may include blend uniformity or appropriate surrogates, granule moisture, tablet weight, hardness, thickness, friability, disintegration, appearance and other process-relevant attributes. Not every test is required at every step for every product; controls should reflect the process and quality risk.

Tablet manufacturing process showing dispensing blending granulation drying milling compression coating and packaging

Liquid and Semi-Solid Pharmaceutical Manufacturing

Solutions, suspensions, emulsions, creams, gels and ointments introduce different process risks than tablets. Typical operations may include purified-water preparation, charging of ingredients, dissolution or dispersion, controlled mixing, heating/cooling, homogenization, deaeration, pH adjustment, bulk holding and filling.

Examples of attributes and parameters that may matter include:

mixing order, time and speed;
temperature profile;
pH;
viscosity or rheology;
particle-size distribution for suspensions;
homogenization conditions;
bulk uniformity;
microbiological control;
maximum bulk hold time;
fill volume or fill weight.

For water-based products especially, water-system control, sanitation, equipment cleanliness and microbial risk can be fundamental to the manufacturing control strategy.

Pharmaceutical dosage form manufacturing routes for solid oral liquid sterile and semi solid pharmaceutical products

Sterile Pharmaceutical Manufacturing - High-Level Overview

Sterile drug manufacturing requires substantially stronger contamination-control systems because a failure can have direct and serious patient-safety consequences. Depending on the product, manufacturing may use terminal sterilization or aseptic processing.

Relevant controls can include cleanroom design and qualification, airflow and pressure controls, environmental monitoring, sterilization/depyrogenation, personnel gowning and aseptic technique, sterile filtration, container-closure integrity, media fills or aseptic process simulations, bioburden control and validated cleaning/disinfection.

Do not apply non-sterile manufacturing assumptions to sterile operations.
Sterile manufacturing is a specialized topic with additional regulations and guidance. The overview here is intentionally high level; detailed aseptic and sterilization requirements require dedicated treatment.

Critical Quality Attributes, Critical Process Parameters and In-Process Controls

Modern pharmaceutical manufacturing relies on understanding the relationship between the product and the process. ICH Q8(R2) provides the Quality by Design framework that includes concepts such as the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), process understanding and control strategy.

A CQA is a physical, chemical, biological or microbiological property or characteristic that should be controlled within an appropriate limit, range or distribution to ensure desired product quality. A CPP is a process parameter whose variability has an impact on a CQA and therefore should be monitored or controlled to ensure the process produces the desired quality.

Concept	Question It Answers	Example
CQA	What product characteristic must be controlled for quality?	Assay, content uniformity, dissolution, impurity level, sterility where applicable
CPP	Which process parameter can materially affect a CQA?	A validated mixing, drying, compression or temperature parameter, where demonstrated critical
IPC	What do we monitor or test during processing to maintain control?	Tablet weight, pH, moisture, blend attribute, fill weight, bioburden as applicable
Control strategy	How do material, process, facility and testing controls work together?	Material specs + parameter ranges + IPC + equipment controls + release testing

Under 21 CFR 211.110, manufacturers must establish and follow control procedures to monitor output and validate the performance of manufacturing processes that may cause variability in the characteristics of in-process material and drug product. In-process controls are therefore not optional decoration; they are part of maintaining process control.

However, a parameter should not be called “critical” merely because it appears on a generic template. Criticality should be supported by product and process knowledge, risk assessment and development or manufacturing data.

CQA CPP and control strategy in pharmaceutical manufacturing showing critical quality attributes process parameters and in process controls

Manufacturing Equipment, Facilities and Utilities

Pharmaceutical manufacturing equipment must be suitable for its intended use, adequately sized, appropriately located, cleanable and maintained so that it does not contaminate product or compromise process control. Examples include mixers, granulators, fluid-bed dryers, mills, tablet presses, capsule fillers, coaters, tanks, homogenizers, filling machines, packaging lines and process-control systems.

Critical supporting utilities can include:

purified water and Water for Injection where applicable;
HVAC and controlled environmental systems;
compressed gases and compressed air;
clean steam;
electrical and automation systems;
temperature-controlled storage systems.

Qualification should demonstrate that critical equipment, facilities and utilities are suitable for their intended use. Health Canada GUI-0029 describes a lifecycle approach and recognizes DQ, IQ, OQ and PQ approaches, while also allowing justified alternative or combined approaches.

For a detailed guide, see Equipment Qualification in Pharmaceutical Industry.

QA, QC and the Quality Unit in Pharmaceutical Manufacturing

Manufacturing and quality functions have different roles but must operate as one controlled system. Production executes the approved process. Quality Control performs sampling, testing and laboratory evaluation. Quality Assurance and the broader quality unit provide oversight of systems, documentation, investigations, change control, validation, training and batch disposition according to company structure and applicable regulations.

Function	Typical Manufacturing Role
Production	Executes approved manufacturing instructions, records operations contemporaneously, performs defined IPCs and reports deviations.
QC	Samples and tests materials, intermediates and finished products; manages analytical data and laboratory investigations.
QA / Quality Unit	Approves or oversees procedures and systems, evaluates deviations and changes, provides validation oversight, reviews records and makes or supports disposition decisions.
Engineering / Validation	Maintains qualified equipment/utilities, supports calibration and maintenance, qualification, process validation and technical changes.

One of the most important CGMP principles is that the quality unit must have adequate authority and responsibility. It should not be forced to approve a batch simply because production targets or supply commitments exist.

Production QA and QC roles in pharmaceutical manufacturing including manufacturing execution quality assurance oversight and quality control testing

Process Validation Lifecycle in Pharmaceutical Manufacturing

FDA's process-validation guidance defines process validation as the collection and evaluation of data, from process design through commercial production, that establishes scientific evidence that a process is capable of consistently delivering quality product.

The FDA lifecycle model is commonly described in three stages:

Stage 1 — Process Design: define and understand the commercial manufacturing process using development and scale-up knowledge.
Stage 2 — Process Qualification: confirm that the facility, equipment and process as designed can perform reproducibly at commercial scale. Process Performance Qualification (PPQ) is central to this stage.
Stage 3 — Continued Process Verification: collect and analyze process and product data during routine production to maintain assurance that the process remains in a state of control.

Health Canada GUI-0029 uses a closely aligned lifecycle structure: process design, PPQ and ongoing process verification. It explicitly emphasizes that validation is not one isolated study-it represents cumulative product and process knowledge across development and commercial manufacture.

“Three validation batches” is not a universal scientific rule.
The number of PPQ batches and the extent of sampling should be scientifically justified based on process understanding, risk, variability and the evidence needed to demonstrate reproducibility. A company procedure may use a default number, but the regulatory lifecycle concept is broader than simply completing three batches.

For detailed coverage of PPQ and continued/ongoing verification, see Process Validation in Pharma.

Pharmaceutical manufacturing validation lifecycle showing process design equipment qualification cleaning validation PPQ and continued process verification

Cleaning, Sanitation and Cross-Contamination Control

Shared manufacturing equipment creates a direct risk that residues from one product, cleaning agent, microorganism, lubricant or other contaminant can affect another batch. CGMP therefore requires appropriate equipment cleaning and maintenance procedures, and the overall manufacturing system must prevent contamination and mix-ups.

A cleaning program can include:

approved cleaning procedures;
defined responsibilities and cleaning frequencies;
cleaning-agent preparation and control;
validated cleaning procedures where required;
residue and microbiological considerations;
dirty and clean hold times where applicable;
visual inspection plus scientifically justified analytical verification;
worst-case product, equipment and sampling-location selection;
ongoing monitoring and change control.

For a dedicated guide, see Cleaning Validation in Pharma.

Master Formula, Batch Records, Documentation and Data Integrity

Pharmaceutical manufacturing must be reproducible not only physically but also documentarily. A batch record provides the traceable history of how a batch was produced and whether the approved process was followed.

Manufacturing documentation generally includes:

master manufacturing or production instructions;
executed batch production records;
equipment identification and usage records;
material lot numbers and quantities;
actual process parameters and IPC results;
yields and reconciliations;
cleaning, calibration and maintenance status where relevant;
deviations, alarms, interventions and investigations;
electronic records and audit trails where computerized systems are used.

21 CFR 211.100 requires written production and process-control procedures to be followed and documented at the time of performance, with deviations recorded and justified. Data-integrity expectations apply whether records are paper, hybrid or electronic.

Batch record and data flow in pharmaceutical manufacturing showing raw material records manufacturing data QC QA review traceability and data integrity

Pharmaceutical Packaging and Labeling

Packaging is a manufacturing control activity, not an afterthought. The container-closure system must protect the product throughout its approved shelf life, and the correct label must be applied to the correct product and batch.

Packaging controls commonly address:

line clearance before the operation;
approved packaging materials and labels;
printed-component control and reconciliation;
prevention of product and label mix-ups;
correct coding of batch number and expiration date;
seal, closure or container-integrity checks;
in-process verification of count, fill, weight or code as applicable;
documented handling of rejects and excess labels.

Finished-Product Testing, Record Review and Batch Release

A manufactured batch is not automatically acceptable because production was completed. Before release, the required laboratory tests and quality review must support that the batch meets applicable specifications and was manufactured in accordance with approved procedures.

Depending on the product, finished-product testing can include identity, assay, impurities, dosage-unit uniformity, dissolution, water or moisture, pH, viscosity, microbial quality, sterility, endotoxins and other product-specific tests.

In the U.S., 21 CFR 211.165 requires appropriate laboratory determination of satisfactory conformance to final specifications before release. Health Canada GUI-0001 similarly places product-release responsibility within the quality-control system and requires evaluation of relevant production documentation and deviations.

HPLC is widely used for many chemical quality tests; see HPLC in Pharmaceutical Quality Control.

Stability Testing and Manufacturing Lifecycle Monitoring

Manufacturing quality does not end at batch release. A product must continue to meet appropriate quality requirements throughout its labeled shelf life under the approved storage conditions.

Stability data can reveal issues that are not obvious in initial release testing-for example degradation, dissolution drift, moisture sensitivity, packaging interactions or changes in physical performance. Manufacturing changes should therefore be evaluated for potential impact on stability commitments and product quality.

For detailed guidance, see Stability Testing in Pharmaceutical Industry.

Batch Manufacturing vs Continuous Manufacturing

Traditional pharmaceutical production is commonly organized as batch manufacturing, where a defined quantity of material moves through discrete processing steps. Continuous manufacturing (CM) integrates material input, processing and output over time, potentially connecting multiple unit operations into an integrated system.

Aspect	Batch Manufacturing	Continuous Manufacturing
Material flow	Discrete defined quantities through unit operations	Ongoing input and output during a defined period of operation
Process integration	Often separated by intermediate storage or transfer	Can integrate several processing steps
Monitoring	Traditional IPC plus process monitoring	Often relies heavily on real-time or near-real-time process understanding and control
Regulatory status	Established approach	Supported by ICH Q13 when scientifically developed and controlled

ICH Q13, finalized by FDA in 2023, provides scientific and regulatory considerations for the development, implementation, operation and lifecycle management of continuous manufacturing for drug substances and drug products.

Continuous manufacturing is not automatically “better” for every product, and batch manufacturing is not inherently outdated. The appropriate platform depends on product, process, supply, technical and regulatory considerations. Both require a robust control strategy and lifecycle quality oversight.

Batch versus continuous pharmaceutical manufacturing comparison showing process flow monitoring scale flexibility and process control

Scale-Up and Technology Transfer

A process that works at laboratory or pilot scale does not automatically behave identically at commercial scale. Scale changes can alter mixing dynamics, heat and mass transfer, drying behavior, shear, residence time, equipment geometry and material flow.

Technology transfer should therefore transfer knowledge, not just a batch record. A strong transfer package can include:

product and process development history;
CQAs, CPPs and key material attributes;
critical equipment characteristics;
proven acceptable ranges or justified operating ranges;
analytical methods and method-transfer requirements;
hold-time information;
cleaning requirements;
known process risks and failure modes;
sampling strategies;
stability and packaging considerations.

Scale-up is a major reason that process design knowledge must be connected to PPQ rather than assuming that development-scale performance guarantees commercial reproducibility.

Deviations, OOS, OOT, Change Control and CAPA in Manufacturing

A mature manufacturing system expects variability and quality events to occur—but controls how they are detected, evaluated and prevented from recurring.

Deviation: departure from an approved procedure, instruction, parameter, expected condition or other controlled requirement.
OOS: a test result outside an established specification or acceptance criterion.
OOT: a result or trend that behaves unexpectedly relative to historical or stability behavior even when it may remain within specification.
Change control: formal evaluation and authorization of proposed changes before implementation.
CAPA: corrective and preventive actions selected from investigation and root-cause understanding.

FDA Requirements for Pharmaceutical Manufacturing - Practical Map

For U.S. finished-drug manufacturing, several 21 CFR Part 211 sections are especially relevant to the manufacturing lifecycle:

Requirement Area	Key 21 CFR Part 211 Sections	Manufacturing Significance
Quality unit	§ 211.22	Independent quality responsibilities and authority
Facilities	§§ 211.42–211.58	Design, flow, sanitation and control of operations
Equipment	§§ 211.63–211.68	Suitability, construction, cleaning, maintenance and automated systems
Components	§§ 211.80–211.94	Receipt, sampling, testing and control of materials and containers/closures
Production/process control	§§ 211.100–211.115	Written procedures, charge-in, yields, IPC, time limits and reprocessing controls
Packaging/labeling	§§ 211.122–211.137	Packaging material, labels, line controls, tamper considerations and expiration dating
Laboratory controls	§§ 211.160–211.176	Specifications, testing, release, stability and reserve samples
Records/investigations	§§ 211.180–211.198	Record retention, batch records, investigations, complaints and review

Three manufacturing provisions are especially important in practice:

21 CFR 211.100: written production/process-control procedures must be designed to assure required identity, strength, quality and purity, approved by appropriate organizational units including the quality control unit, followed in execution, and deviations documented and justified.
21 CFR 211.110: control procedures must monitor output and validate the performance of manufacturing processes that may cause variability in in-process material and drug-product characteristics.
21 CFR 211.192: unexplained discrepancies and specification failures require thorough investigation, appropriate extension of scope, written conclusions and follow-up.

Health Canada Pharmaceutical Manufacturing Expectations

Health Canada GUI-0001 organizes GMP expectations across premises, equipment, personnel, sanitation, raw-material testing, manufacturing control, quality control, packaging materials, finished-product testing, records, samples, stability and sterile products.

Several points are especially relevant to manufacturing:

manufacturing processes should be clearly defined and systematically reviewed;
critical manufacturing steps and key changes should be validated;
equipment should be appropriate for intended use and perform as intended;
manufacturing-control procedures should maintain product integrity from raw-material receipt through finished-product release and distribution;
critical processes should be validated according to predefined protocols;
changes that can affect quality or reproducibility should be evaluated and validated as appropriate before implementation;
quality-control review should include relevant production documentation and deviations;
data-governance controls should apply across the product lifecycle.

Health Canada GUI-0029 further describes a lifecycle validation model and states that process validation should establish process understanding, appropriate control strategies and control of each manufacturing step so that finished product consistently meets requirements.

2026 FDA Warning-Letter Lessons for Pharmaceutical Manufacturers

Recent FDA warning letters illustrate that basic manufacturing-control failures remain active inspection issues. These examples are not a statistical ranking of FDA observations; they are practical case lessons.

Woodbine Products Company - July 2026

FDA cited inadequate written production and process controls, lack of adequate process validation and lack of cleaning validation for non-dedicated equipment. The agency specifically noted the absence of PPQ studies and an adequate ongoing process-monitoring program. The practical lesson is that commercial manufacturing cannot rely on finished-product testing as a substitute for establishing and maintaining process control.

Dabur India Limited - July 2026

FDA cited manufacturing processes that had not been validated for multiple OTC drug products and emphasized lifecycle process validation, including intensive monitoring during qualification and ongoing oversight of process performance and product quality after qualification.

Macau-Union Pharmaceutical - May 2026

FDA cited lack of process validation and inadequate shared-equipment cleaning procedures. The requested remediation included PPQ, ongoing monitoring of intra-batch and inter-batch variation, equipment/facility qualification, cleaning-validation improvements and change-management controls before introducing new manufacturing equipment or products.

Inspection lesson:
A strong manufacturing system must demonstrate control through development knowledge, qualified equipment, validated processes, meaningful in-process controls, reliable records, effective cleaning, investigation of abnormalities and continued monitoring-not by end-product testing alone.

Common Pharmaceutical Manufacturing Mistakes

Treating final testing as the primary quality control: final testing is important but cannot detect or compensate for every process failure.
Running commercial batches before adequate process qualification: commercial urgency does not replace evidence of reproducible control.
Copying generic CPP lists: criticality must be connected to actual product/process understanding.
Weak material controls: supplier documents do not eliminate the manufacturer's responsibility for incoming-material quality.
Missing actual parameters in batch records: if critical times, speeds, temperatures or other data are not recorded, the batch history cannot be properly reconstructed.
Ignoring scale effects: pilot behavior may not predict commercial equipment performance.
Inadequate shared-equipment cleaning controls: cross-contamination risk must be understood and controlled.
Closing deviations without impact assessment: a deviation must be evaluated for batch, process and potentially wider product impact.
Making changes outside formal change control: equipment, material, supplier, software, process or facility changes can alter the validated state.
Stopping validation after PPQ: process validation continues through ongoing/continued process verification.

Pharmaceutical Manufacturing Interview Questions

1. What is the difference between manufacturing and process validation?
Manufacturing is the routine execution of the approved process. Process validation is the lifecycle collection and evaluation of evidence showing that the process can consistently deliver quality product.

2. What is an in-process control?
A control, measurement or test performed during manufacture to monitor process performance or an in-process attribute and help maintain the process in a state of control.

3. What is the difference between CQA and CPP?
A CQA is a product/material quality characteristic that must be appropriately controlled; a CPP is a process parameter whose variability can affect a CQA and therefore requires monitoring or control.

4. Why is line clearance important?
It reduces the risk of product, component, label, document or residue mix-ups between operations.

5. What is PPQ?
Process Performance Qualification confirms at commercial scale that the manufacturing process as designed can perform reproducibly and produce acceptable product under defined conditions.

6. What happens after PPQ?
Process performance and product quality continue to be monitored during routine commercial production to verify an ongoing state of control.

7. Why can a passing finished-product test still be insufficient?
A small sample of finished product may not reveal every source of process variability, contamination or nonuniformity. GMP requires control of the manufacturing process, not only testing of the output.

8. What is the role of change control in manufacturing?
It evaluates proposed changes for impact on quality, validation, regulatory commitments, documentation, training, stability and other affected systems before controlled implementation.

Frequently Asked Questions

What are the main steps in pharmaceutical manufacturing?

A typical drug-product process includes material receipt and testing, release, dispensing, manufacturing unit operations, in-process controls, bulk handling, packaging/labeling, finished-product testing, quality review, batch release and lifecycle monitoring. Exact steps depend on dosage form and process design.

What is GMP in pharmaceutical manufacturing?

Good Manufacturing Practice is the system of regulatory and quality controls used to ensure medicines are consistently produced and controlled to appropriate quality standards. It covers people, facilities, equipment, materials, procedures, production, laboratory controls, records and quality oversight.

What is the difference between production and manufacturing?

In everyday use the terms often overlap. “Production” commonly describes the actual processing operations, while “manufacturing” can be used more broadly to include supporting controls such as material management, packaging, testing, quality review and release. Regulatory language varies by jurisdiction.

What are critical process parameters in pharmaceutical manufacturing?

CPPs are process parameters whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled. They are product/process specific; there is no universal CPP list for every drug.

Does FDA require three process-validation batches?

FDA's lifecycle process-validation guidance does not establish a universal fixed three-batch requirement for every process. The PPQ strategy and number of batches should provide sufficient scientific evidence of reproducibility and control based on process knowledge and risk.

Is continuous manufacturing allowed by FDA?

Yes. FDA finalized ICH Q13 in 2023, which describes scientific and regulatory considerations for continuous manufacturing of drug substances and drug products. Continuous manufacturing still requires an appropriate control strategy and lifecycle management.

Is QC testing enough to ensure pharmaceutical quality?

No. QC testing is an essential part of GMP, but quality must also be built into materials, process design, equipment, procedures, personnel, validation, in-process control, documentation and quality-system oversight.

What is continued process verification?

In FDA's process-validation lifecycle, continued process verification is Stage 3—the ongoing collection and evaluation of process and product data during commercial manufacture to confirm that the process remains in a state of control.

Related Pharma Quality Guides

Official Regulatory Sources

Bottom line

Strong pharmaceutical manufacturing is a lifecycle state of control. Reliable materials, science-based process design, suitable and qualified equipment, trained personnel, approved procedures, meaningful in-process controls, validated processes, effective cleaning, accurate records, laboratory testing and independent quality oversight must work together from raw-material receipt through commercial production and post-release monitoring.